Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norovirus GI.1 Norwalk virus inoculum is a purified infectious stock of the human norovirus genogroup I genotype 1 (GI.1), commonly referred to as the "Norwalk" strain[1][4][5]. It is used primarily in controlled human infection models (CHIM) to study norovirus pathogenesis, immune responses, and to evaluate vaccine efficacy[1][2][5]. The most referenced lot for research purposes is Lot 001-09NV, which has been shown to be stable and infectious over a decade of storage[1]. This standardized viral challenge material enables consistent comparison across studies and supports the development of vaccines against acute gastroenteritis caused by noroviruses[4][5]. The mechanism of action involves direct infection of gastrointestinal epithelial cells leading to self-limited gastroenteritis; it does not act as a therapeutic or preventive drug but rather as an experimental tool for inducing disease in clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Norovirus GI.1 Norwalk virus inoculum.